ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2025 · 102 positions · Total reported value $3.88B · Top-10 concentration 41.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2025 13F filing, ORBIMED ADVISORS LLC disclosed 102 equity positions with a combined reported value of $3.88B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 41.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were EWTX ($251.71M), LLY ($229.82M), SVA ($184.47M). By sector, the heaviest allocations are Health Care 84.3%, Industrials 2.6%. Versus the prior quarter, allocation shifted toward Industrials (+2.1pp), Health Care (+0.9pp) and away from Other (-3.0pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q3 2025 were DHR ($52.16M), UTHR ($48.17M), CI ($46.93M).

Of the 23 positions fully exited versus the prior quarter, the largest were VRTX ($93.62M), THC ($81.84M), CYTK ($35.58M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • DHR DANAHER CORP DEL · $52.16M
  • UTHR UNITED THERAPEUTICS CORP DEL · $48.17M
  • CI THE CIGNA GROUP · $46.93M
  • ABVX ABIVAX SA · $32.26M
  • QURE UNIQURE NV · $26.76M
  • EYPT EYEPOINT INC COM NEW · $25.58M
  • ABT ABBOTT LABORATORIES · $20.09M
  • CARL CARLSMED INC COM · $16.77M

Fully Exited (vs previous quarter)

  • VRTX VERTEX PHARMACEUTICALS INC · prev qtr: $93.62M
  • THC TENET HEALTHCARE CORP · prev qtr: $81.84M
  • CYTK CYTOKINETICS INC COM NEW · prev qtr: $35.58M
  • THRD THIRD HARMONIC BIO INC · prev qtr: $31.38M
  • AGIO AGIOS PHARMACEUTICALS INC COM · prev qtr: $18.56M
  • UNH UNITEDHEALTH GROUP INC · prev qtr: $15.60M
  • KURA KURA ONCOLOGY INC COM · prev qtr: $13.13M
  • ABCL ABCELLERA BIOLOGICS INC COM · prev qtr: $11.47M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 84.3%
Other 13.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 15.52M $251.71M 6.48%
6.48%
Hold
2 301.20K $229.82M 5.92%
5.92%
Reduce
3 2.72M $184.47M 4.75%
4.75%
Hold
4 7.96M $162.93M 4.19%
4.19%
Hold
5 301.60K $137.53M 3.54%
3.54%
Reduce
6 359.20K $132.79M 3.42%
3.42%
Hold
7 1.68M $130.96M 3.37%
3.37%
Reduce
8 287.20K $128.44M 3.31%
3.31%
Reduce
9 172.30K $127.08M 3.27%
3.27%
Reduce
10 3.70M $108.96M 2.81%
2.81%
Hold
11 5.69M $107.10M 2.76%
2.76%
Hold
12 1.42M $93.50M 2.41%
2.41%
Hold
13 3.03M $91.80M 2.36%
2.36%
Hold
14 8.29M $83.30M 2.14%
2.14%
Hold
15 1.64M $71.41M 1.84%
1.84%
Reduce
16 4.00M $70.05M 1.80%
1.80%
Hold
17 1.73M $69.56M 1.79%
1.79%
Add
18 429.30K $69.10M 1.78%
1.78%
Reduce
19 531.80K $64.59M 1.66%
1.66%
Add
20 7.56M $56.80M 1.46%
1.46%
Hold
21 3.03M $55.85M 1.44%
1.44%
Hold
22 1.47M $55.72M 1.43%
1.43%
Add
23 994.62K $54.42M 1.40%
1.40%
Add
24 15.22M $53.27M 1.37%
1.37%
Hold
25 7.17M $52.81M 1.36%
1.36%
Hold
26 263.10K $52.16M 1.34%
1.34%
New
27 353.64K $49.64M 1.28%
1.28%
Reduce
28 114.90K $48.17M 1.24%
1.24%
New
29 162.80K $46.93M 1.21%
1.21%
New
30 3.64M $43.70M 1.12%
1.12%
Add
31 1.77M $43.16M 1.11%
1.11%
Add
32 2.71M $41.07M 1.06%
1.06%
Reduce
33 191.91K $38.15M 0.98%
0.98%
Add
34 2.58M $37.96M 0.98%
0.98%
Hold
35 6.06M $34.36M 0.88%
0.88%
Hold
36 380.00K $32.26M 0.83%
0.83%
New
37 1.14M $31.90M 0.82%
0.82%
Reduce
38 3.31M $30.27M 0.78%
0.78%
Hold
39 290.00K $29.97M 0.77%
0.77%
Reduce
40 2.31M $29.27M 0.75%
0.75%
Add
41 1.09M $28.02M 0.72%
0.72%
Reduce
42 8.46M $26.99M 0.69%
0.69%
Hold
43 2.61M $26.95M 0.69%
0.69%
Hold
44 458.50K $26.76M 0.69%
0.69%
New
45 1.80M $25.58M 0.66%
0.66%
New
46 526.20K $24.98M 0.64%
0.64%
Add
47 5.91M $23.63M 0.61%
0.61%
Hold
48 46.50K $22.55M 0.58%
0.58%
Hold
49 215.15K $21.73M 0.56%
0.56%
Reduce
50 150.00K $20.09M 0.52%
0.52%
New

FAQ

What did ORBIMED ADVISORS LLC buy in 2025-Q3?

In its 2025-Q3 13F filing, ORBIMED ADVISORS LLC reported 102 equity positions worth $3.88B in aggregate; its largest disclosed positions were EWTX ($251.71M), LLY ($229.82M), SVA ($184.47M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $3.88B of long equity holdings across 102 positions as of 2025-Q3. Top-10 holdings account for 41.1% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →